These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8875747)

  • 21. Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status.
    Fukazawa H; Yoshida K; Kaise N; Kiso Y; Sayama N; Mori K; Kikuchi K; Aizawa Y; Rikimaru A; Abe K
    Thyroid; 1995 Oct; 5(5):373-7. PubMed ID: 8563475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
    Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
    Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].
    Ardjomand N; Esche G; Fellner P; Lindner S; Panzitt M; Aigner R; Langmann A
    Ophthalmologe; 2003 Dec; 100(12):1049-53. PubMed ID: 14704818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum L-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids.
    Myśliwiec J; Kretowski A; Szelachowska M; Topolska J; Mikita A; Kinalska I
    Immunol Lett; 2001 Oct; 78(3):123-6. PubMed ID: 11578685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum thyroglobulin changes in patients with Graves' disease treated with long term antithyroid drug therapy.
    Kawamura S; Kishino B; Tajima K; Mashita K; Tarui S
    J Clin Endocrinol Metab; 1983 Mar; 56(3):507-12. PubMed ID: 6185525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
    Wémeau JL; Caron P; Beckers A; Rohmer V; Orgiazzi J; Borson-Chazot F; Nocaudie M; Perimenis P; Bisot-Locard S; Bourdeix I; Dejager S
    J Clin Endocrinol Metab; 2005 Feb; 90(2):841-8. PubMed ID: 15562016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Serum levels of adhesion molecules (sICAM-1, sVCAM-1 and sP-selectin) in children and adolescents with thyroid diseases].
    Bossowski A; Urban M; Citko A; Sobotko J; Bossowska A
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2000; 6(2):79-92. PubMed ID: 12818068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X; Shi B; Li H
    Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
    Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
    Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism.
    Manso PG; Furlanetto RP; Wolosker AM; Paiva ER; de Abreu MT; Maciel RM
    Thyroid; 1998 Jan; 8(1):49-52. PubMed ID: 9492153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy.
    Kruljac I; Solter D; Vrkljan AM; Solter M
    Endocr Res; 2015; 40(1):25-8. PubMed ID: 24833206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triiodothyronine, thyroxine, and iodine in purified thyroglobulin from patients with Graves' disease.
    Izumi M; Larsen PR
    J Clin Invest; 1977 Jun; 59(6):1105-12. PubMed ID: 577211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.
    Baschieri L; Antonelli A; Nardi S; Alberti B; Lepri A; Canapicchi R; Fallahi P
    Thyroid; 1997 Aug; 7(4):579-85. PubMed ID: 9292946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.